Information Provided By: 
Fly News Breaks for November 23, 2015
MSTX
Nov 23, 2015 | 05:28 EDT
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Mast Therapeutics after a specialist told his colleague Josh Schimmer that the company's vepoloxamer is "very interesting" and could be "extremely valuable" at reducing acute vaso-occlusive crisis in sickle cell disease patients. Tenthoff views Mast's risk/reward as attractive into the Phase III EPIC trial data, which is expected in Q2 of 2016. He reiterates an Overweight rating on the stock with a $1 price target. Mast shares closed Friday at 39c.
News For MSTX From the Last 2 Days
There are no results for your query MSTX
